Immune checkpoint inhibition (ICI) has proven therapeutically valuable in non-small cell lung cancer (NSCLC) and other cancers but treatment failure is still seen. Here the authors use multiplex immunofluorescence to visualise the tumour microenvironment in NSCLC to probe functional and metabolic states and correlate this with survival.
- James Monkman
- Aaron Kilgallon
- Arutha Kulasinghe
